Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066957 · ClinicalTrials.gov registry record · Phase 2
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
A Phase 2 study of Cytomegalovirus Infections and Transplant-Related Disorder, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06066957 is a Phase 2 study of Cytomegalovirus Infections and Transplant-Related Disorder that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 80 participants, below the 199-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06066957, a Phase 2 study of Cytomegalovirus Infections and Transplant-Related Disorder, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Open label study to determine tolerability and efficacy of letermovir for CMV prophylaxis in heart and lung transplant recipients. The study hypotheses are: 1. Letermovir prophylaxis will be associated with similar rates of CMV infection as valganciclovir among heart and lung transplant recipients 2. Letermovir will be better tolerated than valganciclovir for CMV prophylaxis in heart and lung transplant recipients, with a higher proportion of days of completed therapy with correct dosing during the planned prophylaxis period 3. Letermovir will have a lower rate of neutropenia than valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients 4. Incorrect renal dosing will occur less frequently with letermovir than with valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients
Conditions Studied
Interventions
- DRUG Letermovir 480 MG [Prevymis]
Study Locations (1)
Pennsylvania
- Penn Medicine at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-04-04 |
| Est. Completion | 2026-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06066957
The ClinicalTrials.gov registry entry for NCT06066957 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (60% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which Letermovir 480 MG [Prevymis] is the first listed.
NCT06066957 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06066957 about?
NCT06066957 is a clinical study titled "Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients". Open label study to determine tolerability and efficacy of letermovir for CMV prophylaxis in heart and lung transplant recipients. The study hypotheses are: 1. Letermovir prophylaxis will be associated with similar rates of CMV infection as valganciclovir among heart and lung transplant recipients ...
What is the current status of trial NCT06066957?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-04-04. Estimated completion is 2026-08-15.
What conditions does trial NCT06066957 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Transplant-Related Disorder.
What interventions are being tested in trial NCT06066957?
The interventions under investigation include: Letermovir 480 MG [Prevymis] (DRUG).
Who is sponsoring clinical trial NCT06066957?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066957 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
RECRUITING · Phase 2
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
-
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
COMPLETED · Phase 2
-
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
COMPLETED · Phase 2
-
Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
COMPLETED · Phase 2
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
Explore more on PlainTrial
Cytomegalovirus Infections
All registered trials for this condition
Transplant-Related Disorder
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.